Jayshree Shah joins Interpath as managing director

Interpath has appointed Jayshree Shah as its new healthcare and life sciences lead. The move comes as the firm continues the expansion of its wider advisory practice.

Commenting on her appointment, Shah said, “Joining Interpath provides me with an excellent opportunity to pursue my passion and to make a real difference to organisations in the Healthcare and Life sciences sector. I’m able to build a team with autonomy that’s not conflicted and draws on specialists from across its multi-disciplinary capabilities to deliver meaningful value for clients.”

As she looks ahead to the future, Shah added she was also “focused on further expanding our value creation team”, as part of Interpath’s growing advisory wing. The firm is looking to expand its advisory offering – which grew much faster last year than its traditional restructuring line – across the deal cycle, as pressure mounts on investors to create value in a difficult market.

Shah is a value creation specialist, and has over 20 years of experience in working with both corporate and private equity clients. Her experience covers a range of advisory services, including value creation, commercial and operational pre-deal diligence, business transformation, accelerated operational cost reduction, carve-outs and post-deal integration.

Previously with PwC and EY, Shah joins Interpath’s London office from FTI Consulting, where she was the EMEA healthcare and life sciences sector lead for corporate finance and restructuring. She will work as a managing director in Interpath’s value creation team, and will also serve as the firm’s sector lead for healthcare and life sciences.

In this role, she will draw on her experience from the sector, as an Association of the British Pharmaceutical industry (ABPI) qualified professional. Shah also has extensive hands-on pharma and healthcare industry experience, having spent half her career working in-house in the industry, including roles at Schering Plough (MSD), Datamonitor Pharma and Amdipharm (now Advanz Pharma).

Commenting on his appointment, Robbie McFaul, transaction services director at Interpath in Leeds, said, “I’ve been impressed by the scale that Interpath and its Deal Advisory team have already achieved, but also the thriving entrepreneurial culture and multi-disciplinary model. It is an exciting place to be and the perfect moment to join as we build a proposition that really challenges the market for the benefit of corporates, investors, and business owners. It is a privilege to join Louise and her team and can’t wait to get stuck in at such a critical period in the regional dealmaking market.”

Interpath now employs more than 160 professionals in its advisory practice, delivering full-service deal advisory, including M&A, transaction services, debt advisory, and M&A tax, as well as forensics, valuations, data analytics, and value creation. The firm advised on more than 130 transactions in 2023.